Full Text View
Tabular View
No Study Results Posted
Related Studies
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
This study has been terminated.
( Repros decided to stop the study because of safety and the FDA decided to put the study on hold because of safety. )
Study NCT00683917   Information provided by Repros Therapeutics Inc.
First Received: May 22, 2008   Last Updated: August 11, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Uterine Fibroids
Additional conditions recognized in this trial
Leiomyoma
Myofibroma
More general conditions related to this trial
Connective Tissue Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Interventions listed in this trial
Proellex 25 mg
Proellex 50 mg
Lupron Depot
Sponsors listed in this trial
Repros Therapeutics Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services